Print

BG Medicine Announces Important New Galectin-3 Findings Presented at American College of Cardiology's 61st Annual Scientific Session & Expo  
3/26/2012 10:22:58 AM

WALTHAM, Mass., March 26, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today the results of several new studies related to the galectin-3 protein. BG Medicine markets a blood test for galectin-3 called the BGM Galectin-3 test for heart failure, which was cleared by the FDA in 2010 and obtained the CE mark for commercialization in the EU. The findings from the studies were presented at a symposium held on Sunday, March 25th at the American College of Cardiology's 61st Annual Scientific Session & Expo. The symposium was sponsored by BG Medicine. In conjunction with these events, the company will host a conference call and webcast this morning at 8:45 a.m. Eastern Time. A summary of the presentations and results is listed below.
//-->